The global pancreatic and bile duct cancer drug market is anticipated to grow at a significant CAGR during the forecast period. Some major factors that are anticipated to drive the market growth include the rising prevalence of pancreatic cancer and cholangiocarcinoma. Pancreatic and bile duct cancer drugs are of different types. Some drugs treat cancer, whereas, others support relieving symptoms such as sickness and pain. 5-fluorouracil, gemcitabine, cisplatin, capecitabine, oxaliplatin are the commonly used drugs for bile duct cancer. Abraxane, Afinitor, erlotinib hydrochloride, everolimus, and 5-FU are among the approved drugs for pancreatic cancer.
The rise in pancreatic cancer patients across the globe due to factors such as age, smoking, diabetes and family history, also drive demand for pancreatic and bile duct cancer drugs. The global pancreatic and bile duct cancer drug market analysis includes some of the key market players such as 3-V Biosciences Inc., 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International Inc., and Ability Pharmaceuticals SL, among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. Further, in December 2021, scientists at Washington University School of Medicine in St. Louis have discovered a drug combination that renders pancreatic cancer cells more vulnerable to chemotherapy. FOLFIRINOX is the first-line treatment for pancreatic cancer, however, only around one out of every three patients will see their tumor shrink. The researchers plan to continue exploring ATI-450 for pancreatic cancer, particularly if this medicine in combination with other investigational treatments, such as immunotherapies, can be effective.
To Request a Sample of our Report on Pancreatic and Bile Duct Cancer Drug Market: https://www.omrglobal.com/request-sample/pancreatic-and-bile-duct-cancer-drug-market
Market Coverage
- The market number available for – 2021-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: 3-V Biosciences Inc., 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International Inc., and Ability Pharmaceuticals SL, among others.
Global Pancreatic and Bile Duct Cancer Drug Market Report Segmentation
By Product Type
- Vascular Endothelial Growth Factor Receptors
- Programmed Cell Death Protein 1
- Others
By Application
- Pancreatic Cancer
- Cholangiocarcinoma
A full Report of Pancreatic and Bile Duct Cancer Drug Market is Available @ https://www.omrglobal.com/industry-reports/pancreatic-and-bile-duct-cancer-drug-market
Pancreatic and Bile Duct Cancer Drug Market by Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pancreatic-and-bile-duct-cancer-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments (0)